OrthoPediatrics (NASDAQ:KIDS) Given "Buy" Rating at BTIG Research

Key Points

• BTIG Research reaffirmed a Buy rating on OrthoPediatrics with a $24.00 price objective, implying roughly a 59.4% upside from the current share price; MarketBeat's consensus is a Moderate Buy with a $24.78 target.
• Shares opened at $15.06 and the company remains unprofitable, though it beat last quarter's estimates (EPS -$0.42 vs. -$0.46 and revenue $59.36M); analysts forecast about -1.07 EPS for the year.
• Insiders sold a total of 58,171 shares (~$1.0M) in the past three months (including the CFO and general counsel), while insiders still own 32.7% of the stock and institutional investors hold about 69.1%.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report)'s stock had its "buy" rating reaffirmed by equities research analysts at BTIG Research in a research note issued to investors on Friday,Benzinga reports. They currently have a $24.00 price objective on the stock. BTIG Research's target price indicates a potential upside of 59.36% from the stock's current price.

Other research analysts also recently issued reports about the company. Wall Street Zen upgraded OrthoPediatrics from a "sell" rating to a "hold" rating in a research report on Saturday, March 7th. Canaccord Genuity Group set a $25.00 price objective on OrthoPediatrics in a research report on Friday, April 24th. Truist Financial lifted their price objective on OrthoPediatrics from $19.00 to $20.00 and gave the stock a "hold" rating in a research report on Monday, March 2nd. Weiss Ratings reiterated a "sell (e+)" rating on shares of OrthoPediatrics in a report on Tuesday, April 21st. Finally, Needham & Company LLC boosted their price target on OrthoPediatrics from $26.00 to $30.00 and gave the company a "buy" rating in a report on Friday, February 27th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $24.78.

OrthoPediatrics Price Performance

Shares of KIDS opened at $15.06 on Friday. The stock's 50 day moving average is $16.73 and its two-hundred day moving average is $17.28. The firm has a market capitalization of $386.89 million, a PE ratio of -8.91 and a beta of 1.16. The company has a current ratio of 5.55, a quick ratio of 2.65 and a debt-to-equity ratio of 0.28. OrthoPediatrics has a twelve month low of $14.42 and a twelve month high of $23.70.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.04. The business had revenue of $59.36 million for the quarter, compared to analyst estimates of $58.29 million. OrthoPediatrics had a negative return on equity of 6.70% and a negative net margin of 16.77%. Research analysts anticipate that OrthoPediatrics will post -1.07 earnings per share for the current year.

Insider Buying and Selling

In other OrthoPediatrics news, CFO Fred Hite sold 12,993 shares of the business's stock in a transaction on Monday, March 16th. The stock was sold at an average price of $17.25, for a total value of $224,129.25. Following the completion of the transaction, the chief financial officer directly owned 277,477 shares in the company, valued at approximately $4,786,478.25. The trade was a 4.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Daniel J. Gerritzen sold 8,614 shares of the company's stock in a transaction on Monday, March 16th. The stock was sold at an average price of $17.25, for a total value of $148,591.50. Following the sale, the general counsel owned 149,533 shares of the company's stock, valued at approximately $2,579,444.25. The trade was a 5.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 58,171 shares of company stock worth $1,003,450 in the last three months. 32.70% of the stock is currently owned by insiders.

Institutional Trading of OrthoPediatrics

Institutional investors and hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. increased its holdings in shares of OrthoPediatrics by 433.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company's stock worth $26,000 after buying an additional 1,139 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in shares of OrthoPediatrics by 5,226.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company's stock worth $46,000 after buying an additional 2,561 shares during the last quarter. Caption Management LLC acquired a new stake in shares of OrthoPediatrics during the 3rd quarter worth $54,000. BNP Paribas Financial Markets increased its holdings in shares of OrthoPediatrics by 60.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company's stock worth $61,000 after buying an additional 1,235 shares during the last quarter. Finally, State of Wyoming increased its holdings in shares of OrthoPediatrics by 189.7% during the 4th quarter. State of Wyoming now owns 6,822 shares of the company's stock worth $121,000 after buying an additional 4,467 shares during the last quarter. 69.05% of the stock is currently owned by institutional investors and hedge funds.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company's product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.